Home / Stocks / BSX

Boston Scientific (BSX, Health Care Equipment) Stock Valuation & Fair Value Fairly valued

Boston Scientific (BSX, Health Care Equipment) trades at a blended P/E of 15.4, about 32% below its historical normal valuation, with a forward growth estimate of 6.8% and a PEG of 2.25. Analysts' one-year estimates have been hit 82% of the time.

DATA AS OF 2026-08-21
Blended P/E
15.4
Normal P/E
22.8
PEG
2.25
Fwd growth
6.8%
Div yield
0.0%
RSI (14)
61.6
Neutral

The Street vs SeerForecast

Wall Street's mean price target for BSX is $62.69 across 29 analysts, 24.5% above the current price. The average analyst rating is Buy. Our SeerForecast read of the same stock, formed without analyst targets: fairly valued. When the two disagree, start your digging there.

Valuation flags

Verdict history

tickerseer's rating has been fairly valued since 2026-06-03.

Price and rating by weekClose moved +8.7 percent from 2026-06-03 to 2026-08-17, with 2 rating changes over 21 recorded weeks.2026-06-03: Fairly valued, close 47.69 (recalculated)2026-06-10: Quality business with a solid forward outlook, close 48.34 (recalculated)2026-06-14: Quality business with a solid forward outlook, close 46.91 (recalculated)2026-06-16: Quality business with a solid forward outlook, close 46.92 (recalculated)2026-06-21: Quality business with a solid forward outlook, close 45.29 (recalculated)2026-07-02: Quality business with a solid forward outlook, close 45.14 (recalculated)2026-07-06: Quality business with a solid forward outlook, close 44.60 (recalculated)2026-07-09: Quality business with a solid forward outlook, close 44.99 (recalculated)2026-07-12: Quality business with a solid forward outlook, close 44.77 (recalculated)2026-07-13: Quality business with a solid forward outlook, close 44.65 (recalculated)2026-07-14: Quality business with a solid forward outlook, close 42.63 (recalculated)2026-07-20: Quality business with a solid forward outlook, close 43.77 (recalculated)2026-07-22: Quality business with a solid forward outlook, close 42.97 (recalculated)2026-07-25: Quality business with a solid forward outlook, close 44.25 (recalculated)2026-07-27: Quality business with a solid forward outlook, close 45.51 (recalculated)2026-07-31: Fairly valued, close 46.73 (recalculated)2026-08-03: Fairly valued, close 46.732026-08-07: Fairly valued, close 49.31 (recalculated)2026-08-10: Fairly valued, close 49.312026-08-14: Fairly valued, close 51.83 (recalculated)2026-08-17: Fairly valued, close 51.8348522026-06-032026-08-17
Attractively valuedFairly valuedAbove fair valueLarger dot: a stronger reading

Not every point was recorded live. Points marked recalculated apply today's valuation rules to the metrics tickerseer archived that week.

2026-06-03P/E 15.4-32%Fairly valued
2026-06-10P/E 15.2-33%Quality business with a solid forward outlook
2026-06-14P/E 15.2-33%Quality business with a solid forward outlook
2026-06-16P/E 15.2-33%Quality business with a solid forward outlook
2026-06-21P/E 15.2-33%Quality business with a solid forward outlook
2026-07-02P/E 13.4-41%Quality business with a solid forward outlook
2026-07-06P/E 14.1-38%Quality business with a solid forward outlook
2026-07-09P/E 14.1-38%Quality business with a solid forward outlook
2026-07-12P/E 13.9-39%Quality business with a solid forward outlook
2026-07-13P/E 13.9-39%Quality business with a solid forward outlook
2026-07-14P/E 13.9-39%Quality business with a solid forward outlook
2026-07-20P/E 13.7-40%Quality business with a solid forward outlook
2026-07-22P/E 13.7-40%Quality business with a solid forward outlook
2026-07-25P/E 13.7-40%Quality business with a solid forward outlook
2026-07-27P/E 13.7-40%Quality business with a solid forward outlook
2026-07-31P/E 14.4-37%Fairly valued
2026-08-03P/E 14.6-36%Fairly valued
2026-08-07P/E 15.4-32%Fairly valued
2026-08-10P/E 15.4-32%Fairly valued
2026-08-14P/E 16.1-29%Fairly valued
2026-08-17P/E 16.1-29%Fairly valued
2026-08-21P/E 15.4-32%Fairly valued ← now

Frequently asked questions

Is Boston Scientific stock overvalued?

At a blended P/E of 15.4 versus its historical normal P/E of 22.8, Boston Scientific trades about 32% below its typical valuation, with a PEG of 2.25 on 6.8% forward growth. tickerseer currently rates it fairly valued.

What is Boston Scientific's fair value and PEG?

Boston Scientific trades at a blended P/E of 15.4 against a historical normal P/E of 22.8, a PEG of 2.25, and a forward growth estimate of 6.8%.

Has tickerseer's rating of Boston Scientific changed?

tickerseer's rating has been fairly valued since 2026-06-03.

What is the analyst price target for Boston Scientific?

The mean Wall Street price target for Boston Scientific is $62.69 across 29 analysts, 24.5% above the current price. tickerseer's SeerForecast verdict is formed independently of analyst targets.

Industry: Health Care Equipment. Create a free account to see the full analysis: the SeerAI score, its five quality sub-scores, valuation history, and the AI research note. Options setups and metric history are part of the paid plans.

See the full analysis →🔔 Track BSX free: valuation & earnings alerts

Get the free weekly earnings preview

One email each Monday with the week's named earnings setups, the reasoning, and what settled last week. Strikes and sizing stay in Premium.

It's free, and you can unsubscribe any time. Educational content, not investment advice.